Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 10Thoracic 3Head & Neck 3Gastrointestinal 3Other solid neoplasm 2Breast 2Sarcoma 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Glioblastoma 5von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 3Magnetic Resonance Spectroscopy 3Trastuzumab 2Nivolumab 2Fluorodeoxyglucose F18 2FAPI-46 2Bevacizumab 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1spartalizumab 1sapanisertib 1sacituzumab govitecan 1relatlimab 1regorafenib 1pertuzumab 1pazopanib 1palbociclib 1osimertinib 1oncogene protein E7, Human papillomavirus type 16 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × spartalizumab × CNS × Clear all
NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

LigaChem Biosciences, Inc.

Phase 1/2 Recruiting
300 enrolled
BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡